A pharmacokinetic model for tenidap in normal volunteers and rheumatoid arthritis patients

Pharmaceutical Research

Volumn 16, Issue 10, 1999, Pages 1608-1615

  Evans, Lynne ^a   Aarons, Leon ^a   Coates, Peter ^b,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Covariates; EM algorithm; Nonlinear mixed effects modelling; Pharmacokinetics; Tenidap

Indexed keywords

ANTIRHEUMATIC AGENT; TENIDAP;

ADULT; AGED; ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; STEADY STATE;

ADULT; AGED; AGING; ALGORITHMS; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; REGRESSION ANALYSIS; SERUM ALBUMIN; SEX CHARACTERISTICS;

EID: 0032712091     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018969024101     Document Type: Article

References (10)

1. T. Pullar. The pharmacokinetics of tenidap sodium: introduction. Br. J. Clin. Pharmac. 39:1S-2S (1995).
2. W. D. Blackburn, H. M. Prupas, J. C. Silverfield, J. E. Poiley, J. R. Caldwell, R. L. Collins, M. J. Miller, D. H. Sikes, H. Kaplan. R. Fleischmann, C. D. Scoville, J. E. Rutstein, E. R. Hurd, J. S. Louie, A. D. Bankhurst, A. L. Weaver, A. I. Sebba, D. J. Appelrouth, N. P. Hudson, G. V. Gordon, R. D. Gordon, C. L. Ludivico, M. C. Austin, K. M. Sanders, P. T. Schuette, R. A. Moidel, A. R. Kraska, N. Ting, W. R. Shanahan, and L. D. Loose. Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone. Arthritis Rheum. 38:1447-1456 (1995).
3. R. Luqmani, C. Gordon, and P. Bacon. Clinical pharmacology and modification of autoimmunity and inflammation in rheumatoid disease. Drugs 47:259-285 (1994).
4. M. J. Gardner, K. D. Wilner, R. A. Hansen, H. G. Fouda, and G. F. McMahon. Single and multiple dose pharmacokinetics of tenidap sodium in healthy subjects. Br. J. Clin. Pharmac 39:11S-15S (1995).
5. J. R. Caldwell, D. S. Kirby, M. J. Gardner, and R. A. Hansen. The effects of age and gender on the pharmacokinetics of tenidap sodium in patients with rheumatoid arthritis and osteoarthritis. Br. J. Clin. Pharmac. 39:3S-9S (1995).
6. M. J. Avery, D. Y. Mitchell, F. C. Falkner, and H. G. Fouda. Simultaneous determination of tenidap and its stable isotope analog in serum by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry. Biol. Mass Spectrometry 21:353-357 (1992).
7. SIPHAR Users Manual. SIMED-Centres D'Etudes et de Recherches en Statistiques et Informatique Medicales, 1988.
8. L. Aarons. The estimation of population pharmacokinetic parameters using an EM algorithm. Comp. Meth. Prog. Biomed. 41:9-16 (1993).
9. J. G. Wagner. Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications Inc., 1979.
10. V. K. Piotrovskii. The use of Weibull distribution to describe the in vivo absorption kinetics. J. Pharmacokin. Biopharm. 15:681-686 (1987).